{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:20:42Z","timestamp":1792840842128,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017246","name":"Academy of Forensic Science Shanghai Key Laboratory of Forensic Medicine","doi-asserted-by":"publisher","award":["KF202304"],"award-info":[{"award-number":["KF202304"]}],"id":[{"id":"10.13039\/100017246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.taap.2025.117352","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T11:54:31Z","timestamp":1745322871000},"page":"117352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Rat-to-human PBPK model of U-47700: Unveiling pharmacokinetic risks of a synthetic opioid through interspecies extrapolation"],"prefix":"10.1016","volume":"499","author":[{"given":"Lina","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.taap.2025.117352_bb0005","article-title":"Treating non-fentanyl-derived synthetic opioid overdose with a traditional opioid reversal agent","volume":"12","author":"Acuna","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.taap.2025.117352_bb0015","author":"Administration"},{"issue":"Pt A","key":"10.1016\/j.taap.2025.117352_bb0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.neuropharm.2017.08.016","article-title":"Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace","volume":"134","author":"Baumann","year":"2018","journal-title":"Neuropharmacology"},{"issue":"11","key":"10.1016\/j.taap.2025.117352_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci10110895","article-title":"U-47700 and its analogs: non-fentanyl synthetic opioids impacting the recreational drug market","volume":"10","author":"Baumann","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.taap.2025.117352_bb0030","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/164_2018_149","article-title":"Synthetic opioids","volume":"252","author":"Beardsley","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"issue":"28","key":"10.1016\/j.taap.2025.117352_bb0035","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1021\/jm00150a017","article-title":"Factors affecting binding of trans-N-[(2-methylamino)cyclohexyl]benzamides at the primary morphine receptor","volume":"1985","author":"Cheney","year":"1985","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.taap.2025.117352_bb0040","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1021\/jm00150a017","article-title":"Factors affecting binding of trans-N-[2-(methylamino)cyclohexyl]benzamides at the primary morphine receptor","volume":"28","author":"Cheney","year":"1985","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.taap.2025.117352_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2019.109999","article-title":"Distribution of synthetic opioids in postmortem blood, vitreous humor and brain","volume":"305","author":"Chesser","year":"2019","journal-title":"Forensic Sci. Int."},{"issue":"4","key":"10.1016\/j.taap.2025.117352_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11040168","article-title":"Interpretation of non-clinical data for prediction of human pharmacokinetic parameters: in vitro-in vivo extrapolation and allometric scaling","volume":"11","author":"Choi","year":"2019","journal-title":"Pharmaceutics"},{"issue":"219","key":"10.1016\/j.taap.2025.117352_bb0010","first-page":"79389","article-title":"Department of Justice, Schedules of Controlled Substances: Temporary Placement of U-47700 Into Schedule I","volume":"81","author":"Drug Enforcement Administration","year":"2016","journal-title":"Final order. Federal register"},{"issue":"8","key":"10.1016\/j.taap.2025.117352_bb0065","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/dta.1984","article-title":"The first reported fatality associated with the synthetic opioid 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700) and implications for forensic analysis","volume":"8","author":"Elliott","year":"2016","journal-title":"Drug Test Anal."},{"issue":"1","key":"10.1016\/j.taap.2025.117352_bb0070","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1038\/s41598-017-06778-9","article-title":"Updating the list of known opioids through identification and characterization of the new opioid derivative 3,4-dichloro-N-(2-(diethylamino)cyclohexyl)-N-methylbenzamide (U-49900)","volume":"7","author":"Fabregat-Safont","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.taap.2025.117352_bb0075","author":"FDA"},{"key":"10.1016\/j.taap.2025.117352_bb0080","author":"Information"},{"issue":"1","key":"10.1016\/j.taap.2025.117352_bb0085","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1208\/s12248-009-9088-1","article-title":"Modelling and PBPK simulation in drug discovery","volume":"11","author":"Jones","year":"2009","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.taap.2025.117352_bb0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/15563650.2016.1209767","article-title":"A case of U-47700 overdose with laboratory confirmation and metabolite identification","volume":"55","author":"Jones","year":"2017","journal-title":"Clin. Toxicol. (Phila.)"},{"issue":"1","key":"10.1016\/j.taap.2025.117352_bb0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/dta.2228","article-title":"Metabolism of novel opioid agonists U-47700 and U-49900 using human liver microsomes with confirmation in authentic urine specimens from drug users","volume":"10","author":"Krotulski","year":"2018","journal-title":"Drug Test Anal."},{"key":"10.1016\/j.taap.2025.117352_bb0100","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.toxlet.2020.04.001","article-title":"Are pigs a suitable animal model for in vivo metabolism studies of new psychoactive substances? A comparison study using different in vitro\/in vivo tools and U-47700 as model drug","volume":"329","author":"Nordmeier","year":"2020","journal-title":"Toxicol. Lett."},{"issue":"12","key":"10.1016\/j.taap.2025.117352_bb0105","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1007\/s00204-021-03169-y","article-title":"Toxicokinetics of U-47700, tramadol, and their main metabolites in pigs following intravenous administration: is a multiple species allometric scaling approach useful for the extrapolation of toxicokinetic parameters to humans?","volume":"95","author":"Nordmeier","year":"2021","journal-title":"Arch. Toxicol."},{"issue":"5","key":"10.1016\/j.taap.2025.117352_bb0110","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/jat\/bkab044","article-title":"Perimortem distribution of U-47700, tramadol and their main metabolites in pigs following intravenous administration","volume":"46","author":"Nordmeier","year":"2022","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.taap.2025.117352_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.107023","article-title":"IUPHAR review: recent progress in the development of Mu opioid receptor modulators to treat opioid use disorders","volume":"199","author":"Pagare","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.taap.2025.117352_bb0120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jps.10005","article-title":"Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution","volume":"91","author":"Poulin","year":"2002","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.taap.2025.117352_bb0125","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1093\/jat\/bkx081","article-title":"U-47700: a not so new opioid","volume":"42","author":"Rohrig","year":"2018","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.taap.2025.117352_bb0130","article-title":"Trends in co-prescribed opioids and benzodiazepines, non-prescribed opioids and benzodiazepines, and schedule-I drugs in the United States, 2013 to 2019","volume":"38","author":"Taha","year":"2024","journal-title":"Prev. Med. Rep."},{"key":"10.1016\/j.taap.2025.117352_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108195","article-title":"Pharmacodynamics and pharmacokinetics of the novel synthetic opioid, U-47700, in male rats","volume":"177","author":"Truver","year":"2020","journal-title":"Neuropharmacology"},{"issue":"14","key":"10.1016\/j.taap.2025.117352_bb0140","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/15287394.2019.1652215","article-title":"Model qualification of the PK-Sim\u00ae pediatric module for pediatric exposure assessment of CYP450 metabolized compounds","volume":"82","author":"Yun","year":"2019","journal-title":"J. Toxicol. Environ. Health A"},{"key":"10.1016\/j.taap.2025.117352_bb0145","doi-asserted-by":"crossref","first-page":"103152","DOI":"10.1016\/j.jddst.2022.103152","article-title":"Applications of PBPK\/PBBM modeling in generic product development: an industry perspective","volume":"69","author":"Yuvaneshwari","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol"}],"updated-by":[{"DOI":"10.1016\/j.taap.2025.117370","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000}}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X25001280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X25001280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T01:50:18Z","timestamp":1762221018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X25001280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":27,"alternative-id":["S0041008X25001280"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2025.117352","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rat-to-human PBPK model of U-47700: Unveiling pharmacokinetic risks of a synthetic opioid through interspecies extrapolation","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2025.117352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117352"}}